マラソンレクチャー
Alzheimer病疾患修飾治療に必要な知識
2025 年 42 巻 4 号 p. 728-731
詳細
2025 年 42 巻 4 号 p. 728-731
Alzheimer disease (AD) is the most common underlying disease of dementia. AD is a neurodegenerative disease, pathologically characterized by senile plaques composed of amyloid β–protein (Aβ), neurofibrillary tangles composed of phosphorylated tau protein, and neuronal cell death. Until now, only symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists have been available, but in 2024, lecanemab, the first disease–modifying therapy (DMT) that primarily targets protofibrils of Aβ, will be released, ushering in a new era of AD treatment.
